Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

Stock factor profile

WANBURY LTD

WANBURY · Healthcare · Pharmaceuticals & Biotechnology

Wanbury Ltd. engages in the business of pharmaceutical and related activities, including research. The company is headquartered in Navi Mumbai, Maharashtra. The firm is engaged in the business of pharmaceutical and related activities, including research. The firm operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. The company has approximately 13 API products. The company manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The firm's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).

Last price₹243.35
1 day-0.67%
1 month-14.97%
Model ratingLocked
Data as of03 Sep 2026

Performance

Price history

Equity review factors

Factor profile

Factor scores are part of the Wright portfolio review.

Run your free portfolio review

Fundamental snapshot

Fundamentals at a glance

Market cap973
P/E ratio13.0
Factor betaLocked
VolatilityLocked
Model scoreLocked
Screen passLocked

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.